Skip to main content

Table 4 Univariate and multivariate analysis of recurrence-free survival (RFS) for breast cancer patients who received adjuvant CIK cell immunotherapy

From: PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Variables

Univariate analysis

Multivariate analysis

HR

95% CI

p value

HR

95% CI

p value

Age (<  50 vs. ≥ 50)

1.084

0.723–1.359

0.689

   

Tumor size (<  20 vs. ≥ 20) (mm)

2.970

1.668–4.515

< 0.001*

1.903

0.311–3.783

0.546

TNM stage (I-II vs. III)

1.803

1.389–3.019

0.020*

1.695

1.119–2.513

0.028*

Histological differentiation (I-II vs. III)

1.015

0.801–1.763

0.812

   

Positive lymph node ratio (< 0.21 vs. ≥ 0.21)

1.997

0.873–3.072

0.065

   

ER (pos vs. neg)

0.582

0.312–1.878

0.475

   

PR (pos vs. neg)

0.718

0.453–2.145

0.327

   

Herb2 (pos vs. neg)

1.510

1.108–2.918

0.035*

1.792

0.589–2.807

0.699

PD-L1 expression (pos vs. neg)

0.596

0.214–0.963

< 0.001*

0.604

0.437–0.895

< 0.001*

TNBC (yes vs. no)

1.958

0.698–3.217

0.760

   
  1. HR Hazard ratio, CI confidence interval; *Statistically significant, p < 0.05